THURSDAY, JULY 20, 2017

Geovax

1900 Lake Park Drive, Suite 380
Atlanta, GA 30080

Geovax News

GeoVax Ebola vaccine successful in rodent models

Investigational Ebola vaccine candidate 100 percent effective in hamsters and guinea pigs Read More »

GeoVax pursues HIV vaccine dual pathway

GeoVax Labs Inc., a biotechnology company that uses its innovative platform technology to create novel vaccines to treat Ebola and HIV, recently announced that it is seeking a dual pathway that will enable its preventive clade B HIV vaccine to advance. Read More »

GeoVax making progress on Ebola vaccine program

GeoVax Labs, Inc., a biotechnology company that uses its unique vaccine delivery platform to create human vaccines, recently gave an update about the progress made in its Ebola vaccine development program. Read More »

Positive data released on GeoVax’s HIV vaccine

GeoVax Labs, Inc. (a biotechnology company specializing in human vaccines with its patent DNA/NVA data) recently presented information about a new HIV vaccine. Read More »